Efficacy, Safety and Dose Selection of AZD3759 in Patients with Untreated <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer and Central Nervous System Metastases in a Phase 2, Multi-Center, Umbrella Trial (CTONG1702)
Si‐Yang Maggie Liu(University of Arizona), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Chong‐Rui Xu(Guangdong Academy of Medical Sciences), Bin-Chao Wang(Guangdong Academy of Medical Sciences), Jiuwei Cui(Jilin University), Xue‐Wu Wei(Guangdong Academy of Medical Sciences), Chang Lu(County Hospital), Yue‐Li Sun(Guangdong Academy of Medical Sciences), Ming-Ying Zheng(Guangdong Academy of Medical Sciences), Xiaorong Dong(The University of Melbourne), Mei-Mei Zheng(Guangdong Provincial People's Hospital), Qing Zhou(Jiangnan University), Zhen Wang(Ministry of Education), Jin‐Ji Yang(Guangdong General Hospital), Mingyi Yang(Guangdong Academy of Medical Sciences), Jie Huang(Sun Yat-sen University), Anna Li(Nuffield Orthopaedic Centre), Xiaoyan Bai(Dalian Medical University), Hua‐Jun Chen(Fujian Medical University), Yingying Du(Second Military Medical University), Bing-Fei Xu(Guangdong Academy of Medical Sciences), Jia‐Yi Deng(Kaohsiung Chang Gung Memorial Hospital), Yang-Si Li(Guangdong Academy of Medical Sciences), Qian Chu(Tongji Hospital), Hong‐Hong Yan(Sun Yat-sen University)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k